HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection

Journal of Immunology

Volumn 183, Issue 4, 2009, Pages 2708-2717

  Bonsignori, Mattia ^a   Moody, M Anthony ^a   Parks, Robert J ^a   Holl, T Matt ^a   Kelsoe, Garnett ^a   Hicks, Charles B ^a   Vandergrift, Nathan ^a   Tomaras, Georgia D ^a   Haynes, Barton F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIRETROVIRUS AGENT; GLYCOPROTEIN GP 120 ANTIBODY; GLYCOPROTEIN GP 41 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; P55 GAG ANTIBODY; RECOMBINANT GLYCOPROTEIN GP 120; TETANUS TOXOID; UNCLASSIFIED DRUG; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PRIORITY JOURNAL; VACCINATION; AMINO ACID SEQUENCE; B LYMPHOCYTE; BIOSYNTHESIS; BLOOD; CELL CULTURE; CHRONIC DISEASE; COMPARATIVE STUDY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; VIROLOGY;

ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; B-LYMPHOCYTE SUBSETS; CELLS, CULTURED; CHRONIC DISEASE; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA;

EID: 70149098269     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901068     Document Type: Article

References (60)

1. Johnston, M. I., and A. S. Fauci. 2008. An HIV vaccine: challenges and prospects. N. Engl. J. Med. 359: 888-890.
2. Hall, H. I., R. Song, P. Rhodes, J. Prejean, Q. An, L. M. Lee, J. Karon, R. Brookmeyer, E. H. Kaplan, M. T. McKenna, and R. S. Janssen; for the HIV Incidence Surveillance Group. 2008. Estimation of HIV incidence in the United States. J. Am. Med. Assoc. 300: 520-529.
3. Fauci, A. S., M. I. Johnston, C. W. Dieffenbach, D. R. Burton, S. M. Hammer, J. A. Hoxie, M. Martin, J. Overbaugh, D. I. Watkins, A. Mahmoud, and W. C. Greene. 2008. HIV vaccine research: the way forward. Science 321: 530-532.
4. Wong, S. B. J., and R. F. Siliciano. 2007. Biology of early infection and impact on vaccine design. In AIDS Vaccine Development: Challenges and Opportunities. P. K. Wayne, C. Koff, and I. D. Gust, eds. Caister Academic Press, Wymondham, UK, pp. 17-22.
5. Dörner, T., and A. Radbruch. 2007. Antibodies and B cell memory in viral immunity. Immunity 27: 384-392.
6. Cagigi, A., A. Nilsson, A. De Milito, and F. Chiodi. 2008. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design. Vaccine 26: 3016-3025.
7. Radbruch, A., G. Muehlinghaus, E. O. Luger, A. Inamine, K. G. Smith, T. Dorner, and F. Hiepe. 2006. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6: 741-750.
8. Shokrgozar, M. A., M. R. Sam, A. Amirkhani, and F. Shokri. 2006. Frequency analysis of HBsAg-specific B lymphocytes in high-responder individuals to recombinant hepatitis B vaccine: comparison of LDA and ELISPOT assays. Scand. J. Immunol. 64: 536-543.
9. Manz, R. A., M. Lohning, G. Cassese, A. Thiel, and A. Radbruch. 1998. Survival of long-lived plasma cells is independent of antigen. Int. Immunol. 10: 1703-1711.
10. Slifka, M. K., and R. Ahmed. 1998. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr. Opin. Immunol. 10: 252-258.
11. Amanna, I. J., N. E. Carlson, and M. K. Slifka. 2007. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357: 1903-1915.
12. Leyendeckers, H., M. Odendahl, A. Löhndorf, J. Irsch, M. Spangfort, S. Miltenyi, N. Hunzelmann, M. Assenmacher, A. Radbruch, and J. Schmitz. 1999. Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Eur. J. Immunol. 29: 1406-1417.
13. Tomaras, G. D., N. L. Yates, P. Liu, L. Qin, G. G. Fouda, L. L. Chavez, A. C. Decamp, R. J. Parks, V. C. Ashley, J. T. Lucas, et al. 2008. Initial B cell responses to transmitted HIV-1: virion-binding IgM and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82: 12449-12463.
14. Gilbert, P. B., M. L. Peterson, D. Follmann, M. G. Hudgens, D. P. Francis, M. Gurwith, W. L. Heyward, D. V. Jobes, V. Popovic, S. G. Self, et al. 2005. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191: 666-677.
15. Blink, E. J., A. Light, A. Kallies, S. L. Nutt, P. D. Hodgkin, and D. M. Tarlinton. 2005. Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization. J. Exp. Med. 201: 545-554.
16. Wrammert, J., K. Smith, J. Miller, W. A. Langley, K. Kokko, C. Larsen, N.-Y. Zheng, I. Mays, L. Garman, C. Helms, et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453: 667-671.
17. Crotty, S., R. D. Aubert, J. Glidewell, and R. Ahmed. 2004. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods 286: 111-122.
18. Newman, J., J. S. Rice, C. Wang, S. L. Harris, and B. Diamond. 2003. Identification of an antigen-specific B cell population. J. Immunol. Methods 272: 177-187.
19. Liao, H. X., L. L. Sutherland, S. M. Xia, M. E. Brock, R. M. Scearce, S. Vanleeuwen, S. M. Alam, M. McAdams, E. A. Weaver, Z. Camacho, et al. 2006. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353: 268-282.
20. Kalyuzhny, A., and S. Stark. 2001. A simple method to reduce the background and improve well-to-well reproducibility of staining in ELISPOT assays. J. Immunol. Methods 257: 93-97.
21. Bernasconi, N. L., E. Traggiai, and A. Lanzavecchia. 2002. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298: 2199-2202.
22. Titanji, K., A. De Milito, A. Cagigi, R. Thorstensson, S. Grutzmeier, A. Atlas, B. Hejdeman, F. P. Kroon, L. Lopalco, A. Nilsson, and F. Chiodi. 2006. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 108: 1580-1587.
23. Crotty, S., P. Felgner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed. 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171: 4969-4973.
24. Tuaillon, E., Y. A. Tabaa, G. Petitjean, M. F. Huguet, G. Pajeaux, J. M. Fondere, B. Ponseille, J. Ducos, P. Blanc, and J. P. Vendrell. 2006. Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBV-immunized subjects by ELISPOT assay. J. Immunol. Methods 315: 144-152.
25. Crotty, S., R. D. Aubert, J. Glidewell, and R. Ahmed. 2004. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods 286: 111-122.
26. Kacani, L., G. M. Sprinzl, A. Erdei, and M. P. Dierich. 1999. Interleukin-15 enhances HIV-1-driven polyclonal B-cell response in vitro. Exp. Clin. Immunogenet. 16: 162-172.
27. Crompton, P. D., M. Mircetic, G. Weiss, A. Baughman, C. Y. Huang, D. J. Topham, J. J. Treanor, I. Sanz, F. E. Lee, A. P. Durbin, et al. 2009. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J. Immunol. 182: 3318-3326.
28. Montero, M., N. E. van Houten, X. Wang, and J. K. Scott. 2008. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 72: 54-84.
29. Haynes, B. F., and D. C. Montefiori. 2006. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5: 579-595.
30. Alam, S. M., R. M. Scearce, R. J. Parks, K. Plonk, S. G. Plonk, L. L. Sutherland, M. K. Gorny, S. Zolla-Pazner, S. Vanleeuwen, M. A. Moody, et al. 2008. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82: 115-125.
31. Alam, S. M., R. M. Scearce, R. J. Parks, K. Plonk, S. G. Plonk, L. L. Sutherland, M. K. Gorny, S. Zolla-Pazner, S. Vanleeuwen, M. A. Moody, et al. 2008. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82: 115-125.
32. Xu, J. Y., M. K. Gorny, T. Palker, S. Karwowska, and S. Zolla-Pazner. 1991. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J. Virol. 65: 4832-4838.
33. Morris, L., J. M. Binley, B. A. Clas, S. Bonhoeffer, T. P. Astill, R. Kost, A. Hurley, Y. Cao, M. Markowitz, D. D. Ho, and J. P. Moore. 1998. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J. Exp. Med. 188: 233-245.
34. Walker, B. D., and D. R. Burton. 2008. Toward an AIDS vaccine. Science 320: 760-764.
35. Nanan, R., D. Heinrich, M. Frosch, and H. W. Kreth. 2001. Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory B-lymphocytes. Vaccine 20: 498-504.
36. Zuckier, L. S., L. D. Rodriguez, and M. D. Scharff. 1989. Immunologic and pharmacologic concepts of monoclonal antibodies. Semin. Nucl. Med. 19: 166-186.
37. Hart, M. K., T. J. Palker, T. J. Matthews, A. J. Langlois, N. W. Lerche, M. E. Martin, R. M. Scearce, C. McDanal, D. P. Bolognesi, and B. F. Haynes. 1990. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J. Immunol. 145: 2677-2685.
38. Haynes, B. F., J. V. Torres, A. J. Langlois, D. P. Bolognesi, M. B. Gardner, T. J. Palker, R. M. Scearce, D. M. Jones, M. A. Moody, and C. McDanal. 1993. Induction of HIVMN neutralizing antibodies in primates using a prime- boost regimen of hybrid synthetic gp120 envelope peptides. J. Immunol. 151: 1646-1653.
39. Anderson, K. P., C. Lucas, C. V. Hanson, H. F. Londe, A. Izu, T. Gregory, A. Ammann, P. W. Berman, and J. W. Eichberg. 1989. Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1. J. Infect. Dis. 160: 960-969.
40. Adalid-Peralta, L., L. Grangeot-Keros, A. Rudent, N. Ngo-Giang-Huong, R. Krzysiek, C. Goujard, C. Deveau, M. Le Gall, L. Meyer, D. Emilie, and C. Rouzioux. 2006. Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection. HIV Med. 7: 514-519.
41. Markowitz, M., M. Vesanen, K. Tenner-Racz, Y. Cao, J. M. Binley, A. Talal, A. Hurley, X. Ji, M. R. Chaudhry, M. Yaman, et al. 1999. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J. Infect. Dis. 179: 527-537.
42. Montefiori, D. C., T. S. Hill, H. T. T. Vo, B. D. Walker, and E. S. Rosenberg. 2001. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J. Virol. 75: 10200-10207.
43. Voltersvik, P., G. Albrektsen, E. Ulvestad, A. M. Dyrhol-Riise, B. Sorensen, and B. Asjo. 2003. Changes in immunoglobulin isotypes and immunoglobulin G (IgG) subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremia. J. Acquired Immune Defic. Syndr. 34: 358-367.
44. Hutter, G., D. Nowak, M. Mossner, S. Ganepola, A. Mussig, K. Allers, T. Schneider, J. Hofmann, C. Kucherer, O. Blau, et al. 2009. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360: 692-698.
45. Johnston, M. I., and A. S. Fauci. 2007. An HIV vaccine-evolving concepts. N. Engl. J. Med. 356: 2073-2081.
46. + T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95: 8869-8873.
47. Gasper-Smith, N., D. M. Crossman, J. F. Whitesides, N. Mensali, J. S. Ottinger, S. G. Plonk, M. A. Moody, G. Ferrari, K. J. Weinhold, S. E. Miller, et al. 2008. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J. Virol. 82: 7700-7710.
48. Williams, J. L., C. J. Christensen, B. J. McMahon, L. R. Bulkow, H. H. Cagle, J. S. Mayers, C. L. Zanis, A. J. Parkinson, and H. S. Margolis. 2001. Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. Vaccine 19: 4081-4085.
49. Levesque, M. C., M. A. Moody, K. Hwang, D. J. Marshall, J. F. Whitesides, J. D. Amos, T. C. Gurley, S. Allgood, B. B. Haynes, N. A. Vandergrift, et al. 2009. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med. 6: Epub ahead of print July 7, 2009.
50. Moir, S., J. Ho, A. Malaspina, W. Wang, A. C. DiPoto, M. A. O'Shea, G. Roby, S. Kottilil, J. Arthos, M. A. Proschan, et al. 2008. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J. Exp. Med. 205: 1797-1805.
51. Malaspina, A., S. Moir, S. M. Orsega, J. Vasquez, N. J. Miller, E. T. Donoghue, S. Kottilil, M. Gezmu, D. Follmann, G. M. Vodeiko, et al. 2005. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J. Infect. Dis. 191: 1442-1450. (Pubitemid 40563355)
52. Chirmule, N., V. S. Kalyanaraman, C. Saxinger, F. Wong-Staal, J. Ghrayeb, and S. Pahwa. 1990. Localization of B-cell stimulatory activity of HIV-1 to the carboxyl terminus of gp41. AIDS Res. Hum. Retroviruses 6: 299-305. (Pubitemid 20278791)
53. Weinhold, K. J., H. K. Lyerly, S. D. Stanley, A. A. Austin, T. J. Matthews, and D. P. Bolognesi. 1989. HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J. Immunol. 142: 3091-3097.
54. Shan, M., P. J. Klasse, K. Banerjee, A. K. Dey, S. P. Iyer, R. Dionisio, D. Charles, L. Campbell-Gardener, W. C. Olson, R. W. Sanders, and J. P. Moore. 2007. HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog. 3: e169.
55. He, B., X. Qiao, P. J. Klasse, A. Chiu, A. Chadburn, D. M. Knowles, J. P. Moore, and A. Cerutti. 2006. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J. Immunol. 176: 3931-3941. (Pubitemid 44264370)
56. Goepfert, P. A., G. D. Tomaras, H. Horton, D. Montefiori, G. Ferrari, M. Deers, G. Voss, M. Koutsoukos, L. Pedneault, P. Vandepapeliere, et al. 2007. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 25: 510-518.
57. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200: 749-759.
58. + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77: 11708-11717.
59. + T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200: 761-770.
60. Veazey, R. S., P. A. Marx, and A. A. Lackner. 2001. The mucosal immune system: primary target for HIV infection and AIDS. Trends Immunol. 22: 626-633.